Baseline characteristics of patients who received axi-cel in the mITT cohort
Covariate . | Before PS matching . | After PS matching . | |||||
---|---|---|---|---|---|---|---|
Level . | No BT, N = 132 (%) . | BT, N = 143 (%) . | P value . | No BT, N = 97 (%) . | BT, N = 97 (%) . | P value . | |
Age | ≥65 y | 32 | 31 | .85 | 35 | 29 | .37 |
Sex | Female | 38 | 32 | .26 | 30 | 33 | .64 |
ECOG score | 2-4 | 7 | 24 | <.001 | 9 | 12 | .49 |
Stage III or IV | Yes | 74 | 88 | .004 | 87 | 84 | .68 |
IPI | 3-5 | 36 | 66 | <.001 | 48 | 54 | .47 |
Prior lines of therapy | ≥3 | 70 | 75 | .34 | 70 | 68 | .76 |
Refractory disease | Yes | 72 | 78 | .28 | 71 | 75 | .51 |
Bulky disease | Yes | 13 | 29 | .001 | 17 | 21 | .58 |
Prior auto-SCT | Yes | 37 | 28 | .1 | 32 | 32 | >.99 |
Met ZUMA-1 eligibility | Yes | 70 | 51 | .002 | 64 | 61 | .66 |
Double or triple hit | Yes | 17 | 23 | .16 | 19 | 24 | .5 |
Cell or origin | Non-GCB | 47 | 45 | .77 | 44 | 46 | .9 |
LDH at conditioning | <200 | 27 | 13 | .01 | 22 | 17 | .96 |
200-300 | 21 | 24 | 26 | 26 | |||
300-500 | 23 | 27 | 25 | 26 | |||
≥500 | 24 | 32 | 24 | 27 |
Covariate . | Before PS matching . | After PS matching . | |||||
---|---|---|---|---|---|---|---|
Level . | No BT, N = 132 (%) . | BT, N = 143 (%) . | P value . | No BT, N = 97 (%) . | BT, N = 97 (%) . | P value . | |
Age | ≥65 y | 32 | 31 | .85 | 35 | 29 | .37 |
Sex | Female | 38 | 32 | .26 | 30 | 33 | .64 |
ECOG score | 2-4 | 7 | 24 | <.001 | 9 | 12 | .49 |
Stage III or IV | Yes | 74 | 88 | .004 | 87 | 84 | .68 |
IPI | 3-5 | 36 | 66 | <.001 | 48 | 54 | .47 |
Prior lines of therapy | ≥3 | 70 | 75 | .34 | 70 | 68 | .76 |
Refractory disease | Yes | 72 | 78 | .28 | 71 | 75 | .51 |
Bulky disease | Yes | 13 | 29 | .001 | 17 | 21 | .58 |
Prior auto-SCT | Yes | 37 | 28 | .1 | 32 | 32 | >.99 |
Met ZUMA-1 eligibility | Yes | 70 | 51 | .002 | 64 | 61 | .66 |
Double or triple hit | Yes | 17 | 23 | .16 | 19 | 24 | .5 |
Cell or origin | Non-GCB | 47 | 45 | .77 | 44 | 46 | .9 |
LDH at conditioning | <200 | 27 | 13 | .01 | 22 | 17 | .96 |
200-300 | 21 | 24 | 26 | 26 | |||
300-500 | 23 | 27 | 25 | 26 | |||
≥500 | 24 | 32 | 24 | 27 |
Auto-SCT, autologous stem cell transplant; non-GCB, germinal center B cell.